This company listing is no longer active
Resumen de acción PLX
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Protalix BioTherapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.33 |
| 52 Week High | US$7.80 |
| 52 Week Low | US$3.15 |
| Beta | 1.47 |
| 1 Month Change | 28.98% |
| 3 Month Change | 75.79% |
| 1 Year Change | 97.55% |
| 3 Year Change | -16.86% |
| 5 Year Change | -59.71% |
| Change since IPO | -97.70% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| PLX | IL Biotechs | Mercado IL | |
|---|---|---|---|
| 7D | -0.1% | -2.8% | -4.1% |
| 1Y | 97.5% | -6.1% | 2.6% |
Rentabilidad vs. Industria: PLX exceeded the IL Biotechs industry which returned -49.3% over the past year.
Rentabilidad vs. Mercado: PLX exceeded the IL Market which returned -25.9% over the past year.
Volatilidad de los precios
| PLX volatility | |
|---|---|
| PLX Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IL Market | 8.1% |
| 10% least volatile stocks in IL Market | 3.2% |
Precio estable de las acciones: PLX's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: PLX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1993 | 195 | Dror Bashan | www.protalix.com |
Resumen de fundamentos de Protalix BioTherapeutics, Inc.
| Estadísticas fundamentales de PLX | |
|---|---|
| Capitalización bursátil | ₪407.53m |
| Beneficios(TTM) | -₪54.09m |
| Ingresos (TTM) | ₪172.62m |
2.4x
Ratio precio-ventas (PS)-7.5x
Ratio precio-beneficio (PE)¿Está PLX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PLX | |
|---|---|
| Ingresos | US$47.64m |
| Coste de los ingresos | US$19.59m |
| Beneficio bruto | US$28.05m |
| Otros gastos | US$42.97m |
| Beneficios | -US$14.93m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.26 |
| Margen bruto | 58.87% |
| Margen de beneficio neto | -31.33% |
| Ratio deuda/patrimonio | -264.9% |
¿Cómo se ha desempeñado PLX a largo plazo?
Ver rendimiento histórico y comparativa